Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CP-870,893 + paclitaxel + carboplatin
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
CP-870,893 + paclitaxel + carboplatin is a **combination therapy** of a fully human monoclonal antibody (CP-870,893, also known as Selicrelumab or RO7009789) targeting CD40, with the chemotherapeutic agents paclitaxel and carboplatin. CP-870,893 acts as a CD40 agonist, activating antigen-presenting cells and facilitating immune responses against tumors, as well as directly inducing apoptosis and immune modulation in CD40-positive malignancies. Paclitaxel is a microtubule-stabilizing chemotherapy drug disrupting cell division, while carboplatin is a platinum-based DNA-damaging agent inducing tumor cell death. The combination has been evaluated primarily in patients with advanced solid tumors—including melanoma, ovarian cancer, pancreatic cancer, and renal cell carcinoma—to assess safety, pharmacodynamics, and preliminary antitumor efficacy.
- Other names
- Selicrelumab + paclitaxel + carboplatinRO7009789 + paclitaxel + carboplatin
02
Targets
CD40 (Cluster of differentiation 40 receptor)DNAMicrotubuleTUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on CP-870,893 + paclitaxel + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CP-870,893 + paclitaxel + carboplatin.